论文部分内容阅读
目的 :观察多药耐药相关蛋白 (MRP)在肾母细胞瘤中的表达情况 ,探讨其临床意义。方法 :采用免疫组织化学方法检测 48例肾母细胞瘤、3 6瘤旁肾组织及 14例正常肾组织 (6例胚胎肾、8例重肾组织 )中MRP的表达。结果 :肾母细胞瘤中阳性表达 8例 ,占 16.7% ,瘤旁肾组织中阳性表达 2 2例 ,占 61.1% ,两者差异显著 (P <0 .0 1)。正常肾组织阳性表达者 3例 ,占 2 1.4% ,同瘤旁肾组织组比较差异显著 (P <0 .0 5 )。预后差者 9例 (复发6例 ,死亡 3例 ) ,阳性表达者 5例 ,占 5 5 .6% ,与预后良好者比较 ,差异显著 (P<0 .0 5 )。结论 :MRP在肾母细胞瘤中表达率低于瘤旁组织 ,从蛋白水平上为肾母细胞瘤化疗提供了依据 ,并可以作为判定预后的指标
Objective: To observe the expression of multidrug resistance-related protein (MRP) in Wilms’ tumor and to discuss its clinical significance. Methods: The expression of MRP in 48 cases of nephroblastoma, 3 of tumor adjacent tissues and 14 cases of normal kidney tissue (6 cases of fetal kidney and 8 cases of severe kidney) was detected by immunohistochemical method. Results: The positive expression rate in nephroblastoma was 8 cases (16.7%), and the positive expression in tumor adjacent tissues was 22 (61.1%), with significant difference (P <0.01). There were 3 cases of normal renal tissue positive expression, accounting for 2 1.4%, which was significantly different from that of adjacent renal tissue (P <0.05). There were 9 cases with poor prognosis (6 cases relapsed and 3 cases died), and 5 cases were positive (5 5 .6%), which were significantly different from those with good prognosis (P <0.05). Conclusion: The expression of MRP in nephroblastoma is lower than that of tumor-adjacent tissues, which provides a basis for the chemotherapy of nephroblastoma at the protein level and can be used as an index to judge the prognosis